Stockscreener 앱 받기
733.04
1.20%
-8.88
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Evergreen Capital Management LLC - MarketBeat
Howland Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 4,200 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
Dillon & Associates Inc. Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Basal Cell Carcinoma Treatment Market to Reach US$ 19.6 Billion - openPR.com
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
Trading Recap: What are the future prospects of Regeneron Pharmaceuticals IncMarket Growth Report & Weekly Market Pulse Updates - baoquankhu1.vn
Meritage Portfolio Management Buys 9,486 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Nordea Investment Management AB Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? - Yahoo Finance
JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries - Pharmaceutical Technology
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Benzinga
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
Allergic Rhinitis Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Regeneron Pharma, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB, Hyloris Pharma - Barchart.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Erasca (ERAS) and Connect Biopharma Holdings (CNTB) - The Globe and Mail
Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs - marketscreener.com
JP Morgan 2026: Regeneron Focusing on Broad Pipeline Development - PharmExec.com
JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats - BioSpace
Regeneron Pharmaceuticals (BIT:1REGN) Price Target Increased by 11.61% to 743.10 - Nasdaq
PKO Investment Management Joint Stock Co Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Highlights Growth Strategy and Pipeline at JPM Conference - The Globe and Mail
Regeneron Pharma price target raised to $820 from $800 at Raymond James - Investing.com UK
Market Review: What is the fair value of Regeneron Pharmaceuticals Inc. stock nowBull Run & High Conviction Trade Alerts - Bộ Nội Vụ
Stop Loss: Will Regeneron Pharmaceuticals Inc. stock split attract more investorsJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - Bộ Nội Vụ
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Strong Buy with 15.19% Return on Equity and 3.53% Potential Upside - DirectorsTalk Interviews
Regeneron announcements validate Apogee thesis, says Stifel By Investing.com - Investing.com UK
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Analyst Buy Upgrades - simplywall.st
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Poised for Rapid - openPR.com
A big Wall Street flip just changed the Regeneron narrative - thestreet.com
Regeneron and Sanofi's Dupixent succeeds in late-stage study - MSN
Oregon Public Employees Retirement Fund Has $6.56 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Cerity Partners LLC - MarketBeat
What is the fair value of Regeneron Pharmaceuticals Inc. stock nowJuly 2025 Rallies & Verified Entry Point Signals - ulpravda.ru
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by SG Americas Securities LLC - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to Strong-Buy at Zacks Research - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wall Street Zen - MarketBeat
J&J Deal Adds To Trump Administration MFN Pricing Initiative - Citeline News & Insights
J&J Joins Trump Administration’s MFN Pricing Initiative - Citeline News & Insights
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock? - sharewise.com
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $911 From $818, Maintains Outperform Rating - marketscreener.com
Is Regeneron (REGN) Offering Value After Recent Share Price Strength And DCF Assessment - simplywall.st
Responsive Playbooks and the REGN Inflection - Stock Traders Daily
Regional Court Munich grants PI to Regeneron against generics in Eylea case - JUVE Patent
Regeneron Pharmaceuticals, Inc. $REGN Stake Lifted by Clear Harbor Asset Management LLC - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock benefit from upcoming earnings reportsTrade Ideas & Reliable Entry Point Trade Alerts - ulpravda.ru
How interest rate cuts could boost Regeneron Pharmaceuticals Inc. stock2025 Volatility Report & Capital Efficiency Focused Ideas - ulpravda.ru
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $1,200,000.00 in Stock - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock split again soon2025 Risk Factors & Daily Market Momentum Tracking - ulpravda.ru
Regeneron Pharmaceuticals Director Sells 1,500 Shares - TradingView — Track All Markets
Stock Market Recap: Will Regeneron Pharmaceuticals Inc. stock split again soonMarket Movement Recap & Weekly High Return Stock Forecasts - ulpravda.ru
Truist Securities Raises Price Target for REGN to $820, Maintains Buy Rating | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $820.00 Price Target at Truist Financial - MarketBeat
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Benzinga
Noesis Capital Mangement Corp Has $11.90 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KLP Kapitalforvaltning AS Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Positive mid-stage results for Regeneron’s fasinumab - The Pharma Letter
MassMutual Private Wealth & Trust FSB Buys 1,267 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Retinopathy Market to Witness Remarkable Growth With - openPR.com
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN) - Yahoo Finance
Regeneron Just Moved From Underperform To BuyHere's Why - Benzinga
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday (CORRECTED) - Benzinga
Regeneron Stock Lagged Behind the S&P 500 Last Year. Why It’s a Buy Anyway. - Barron's
Regeneron upgraded at BoA on Eylea HD, Dupixent, and pipeline - Seeking Alpha
1.63%
0.00%
자본화:
|
볼륨(24시간):